GeoVax Labs, Inc. raises $3.0M Private Placement (United States, May 2026)
Find the investors funding Health Private Placement rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules - TradingView
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company is notable for its expedited regulatory pathway for its GEO-MVA vaccine targeting mpox and smallpox, with plans for a pivotal Phase 3 clinical trial in 2026.
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules TradingView
| Sep 23, 2026 | Ema | $77.0M | Series B | United States |
| Sep 23, 2026 | Baselayer | $35.0M | Series A | United States |
| Sep 23, 2026 | Hubble Network | $200.0M | Series C | United States |
| Sep 23, 2026 | Topdog | $2.5M | Seed | United States |
21,374 investors back startups in United States
You just read who funded GeoVax Labs, Inc.. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.